2024
Results of two clinical trials in vulnerable populations support the evaluation of BIO101 (20-hydroxyecdysone), a MAS Receptor activator as a candidate oral treatment for rare pediatric neuromuscular diseases, Cendrine Tourette, Waly Dioh, Sandrine Rabut, Serge Camelo, Jean Mariani, Rob Van Maanen, Stanislas Veillet
BIO101 drug candidate development in rare neuromuscular diseases: Cardiorespiratory and motor unit preclinical evaluation in DMD and in SMA, Pierre Dilda, Cynthia Bézier, Robin Deloux, René Lafont, Stanislas Veillet, Frédéric Charbonnier, Olivier Biondi, Mathilde Latil
BIO101 as a candidate oral treatment for DMD patients is supported by the results of two randomized clinical trials in
vulnerable populations, Cendrine Tourette, Waly Dioh, Sandrine Rabut, Serge Camelo, Jean Mariani, Rob Van Maanen, Stanislas Veillet